Last reviewed · How we verify
NCT05808842
Laser Treatment for Facial and Neck Rejuvenation
NA trial testing CeraVe in Face Rejuvenation in 15 participants. Status unknown.
28 February 2024
Quick facts
| Lead sponsor | Goldman, Butterwick, Fitzpatrick and Groff |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 3 April 2023 |
| Primary completion | 28 February 2024 |
| Estimated completion | 28 February 2024 |
Drugs / interventions tested
- CeraVe
- CeraVe and Calecim
Conditions studied
- Face Rejuvenation — all drugs for Face Rejuvenation →
- Neck Rejuvenation — all drugs for Neck Rejuvenation →
Sponsor
Goldman, Butterwick, Fitzpatrick and Groff — full company profile →
Who can join
Adults 18 to 75, any sex, with Face Rejuvenation or Neck Rejuvenation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the efficacy, safety, and patient satisfaction associated with the treatment of the face and neck with the 2,910nm mid-infrared UltraClear Laser System using both superficial epidermal ablation and deep ablative and coagulative capabilities in the dermis for rejuvenation of photodamaged skin. Additionally, this study will assess the additive value of a post-treatment skincare regimen consisting of a serum and cream containing red deer umbilical cord lining mesenchymal stem cell conditioned media for faster healing and more robust rejuvenation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05808842
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CeraVe
Trials testing the same drug.
- NCT07044024 — An Observational Clinical Study to Evaluate the Efficacy of the CeraVe Skin Care Line · not yet recruiting
Other Goldman, Butterwick, Fitzpatrick and Groff trials
Trials by the same sponsor.
- NCT07462533 — Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing · Phase 2 · not yet recruiting
- NCT07421544 — Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines · Phase 4 · not yet recruiting
- NCT07342413 — Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the · Phase 4 · not yet recruiting
- NCT07221461 — Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists · Phase 2 · not yet recruiting
- NCT07217743 — Assess Impact of Poly-L-lactic Acid on GLP1 Subjects · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05808842 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Goldman, Butterwick, Fitzpatrick and Groff
- Last refreshed: 11 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05808842.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing